Devyser Diagnostics AB (publ) (DVYSR) Earnings Call Transcripts

Devyser Diagnostics AB (publ)'s Latest Earnings Call - Q1 FY2026

Devyser Diagnostics AB reported strong Q1 2026 results, with revenue reaching SEK 62 million, a 13% increase year-over-year, and a positive EBIT of SEK 2.6 million compared to a negative SEK 14.8 million in Q1 2025. The company highlighted a gross margin of 82% and continued profitable growth, driven by strategic partnerships and acquisitions, notably the acquisition of CyberGene. Management maintained a positive outlook, emphasizing ongoing growth initiatives and collaborations with Thermo Fisher and Illumina. No changes were made to forward guidance, but the company expressed confidence in achieving cash flow positivity.

Reported metrics

Guidance from management

Management did not change forward guidance but expressed confidence in achieving cash flow positivity and continued profitable growth.

What management said

I cannot give any exact comments because I don't know the orders coming in the quarters to come. But we see it as a positive sign that we start to get orders in also Q1 and see that it's going to be less lengthy going forward.

I cannot comment on that in detail. But I mean, we -- as I said, we had a positive meeting and we see an onboarding of new customers with the -- on the Thermo side when it comes to our transplantation products. If that is going to show in the numbers going forward, that's still to be seen.

What analysts pressed on

Analysts questioned the sustainability of growth rates and the impact of strategic partnerships on future revenue. Concerns were raised about the visibility of future orders from Thermo Fisher and the financial impact of the Illumina collaboration.

Main topics on the call

• Revenue Growth — Revenue for Q1 2026 was SEK 62 million, up 13% year-over-year, or 24% in fixed currencies. Management attributed growth to strong performance in North America and strategic partnerships.
• Profitability — The company reported a positive EBIT of SEK 2.6 million, marking the fourth consecutive quarter of profitability. This is a significant improvement from the negative SEK 14.8 million in Q1 2025.
• Gross Margin — Gross margin improved to 82%, surpassing the full year 2025 margin. Management plans to continue improving cost of goods sold.
• CyberGene Acquisition — Devyser completed the acquisition of CyberGene, which is expected to enhance its commercial position and contribute positively to gross profit and margin.

Read the full Devyser Diagnostics AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Devyser Diagnostics AB (publ) earnings call transcripts on record, spanning February 21, 2023 to July 20, 2026. Based on this history, Devyser Diagnostics AB (publ) reports quarterly. The most recent call on file is dated July 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DVYSR

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

February 21, 2023

Most recent

July 20, 2026

Reporting cadence

quarterly